| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_306931c55ec7705464a764aab05a1032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f21c1009c60308a64b8e7dc0bb989632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc9d75bedf51340bf01bbaa4d612d989
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52f2e6de1c6f5a3ba7b48c7196e249b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_191663f2561f98d0ba67c91203359033 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 |
| filingDate |
2012-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c8bb8d4baf35f79ebddd93c97d2e866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7c08570b3f38ba82e81741e8e42e762
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb847c80572c3ff3efa8fb896491609c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_904106ab717d9260ac313a8366d2ac92 |
| publicationDate |
2015-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015150911-A2 |
| titleOfInvention |
Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins |
| abstract |
The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. |
| priorityDate |
2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |